「one」の検索結果

Use for deep Vue 3 best-practices review, recommendations, and the full ordered authoring workflow — built-in components (Teleport, Suspense, KeepAlive, Transition, TransitionGroup), animation techniques, slots, fallthrough attrs, custom directives, async components, render functions, plugins, and the post-functionality performance pass. Complements mk:vue (the everyday Composition API quick-reference). Invoke for "review my Vue", "Vue best practices", "recommend improvements", or non-trivial feature work needing the ordered workflow.

日本語の概要は準備中です。原文の説明を表示しています。

Use when writing, reviewing, or refactoring Vue 3 code — components, composables, reactivity, Pinia state, Pinia Colada data-fetching, file-based routing, and forms. Targets Composition API + <script setup> + TypeScript. Auto-activates on .vue files. For deep best-practices review/recommendations or the full ordered workflow (built-in components, animations, performance pass), use mk:vue-best-practices.

日本語の概要は準備中です。原文の説明を表示しています。

Manage JIRA issue relationships via the jira-as wrapper: link, unlink, blockers, dependencies, clone, bulk-link. Triggers: 'link KEY blocks KEY', 'what blocks KEY', 'clone KEY', 'unlink KEY from KEY'. NOT for sprint/epic relationships (mk:jira-agile).

日本語の概要は準備中です。原文の説明を表示しています。

Use when copy-catting, replicating, or adapting features from external systems, repos, apps, or ideas into the current project. Triggers on 'copy this from', 'replicate', 'clone this feature', 'how does X do Y', 'chom', 'like how X does it', 'port from', 'build like', '1:1 copy'. NOT for packing the current project (see mk:pack); NOT for one-shot URL-to-markdown fetches (see mk:web-to-markdown).

日本語の概要は準備中です。原文の説明を表示しています。

Relentlessly interview the user about THEIR plan or design — one question at a time — resolving each branch of a decision tree until shared understanding. Claude is the interviewer; the user is the interviewee. Triggers on "grill me", "stress-test this plan", "get grilled on my design", "interrogate my plan". Checkpoints every answer to docs/knowledge/<slug>.md so progress survives a context-window reset. Flags knowledge the user cannot answer as a gap to chase. Do NOT use to PROPOSE solutions or compare approaches (→ mk:brainstorming). Do NOT use to validate "is this worth building?" (→ mk:office-hours). Do NOT use when Claude should ANSWER questions about the repo (→ mk:ask-me). Do NOT use for a one-shot review of an existing plan (→ mk:plan-ceo-review). Do NOT use to apply named reasoning lenses to findings (→ mk:elicit).

日本語の概要は準備中です。原文の説明を表示しています。

GitHub project management via the gh CLI — create and triage issues, manage GitHub Projects v2 boards (add items, update status fields), manage labels and milestones, and generate handoff-status summaries. Use when "create a GitHub issue", "add to project board", "update sprint status", "create label/milestone", or "give me a handoff summary of open work". NOT for code review (see mk:review-pr); NOT for PR creation (see mk:ship); NOT for git operations (see mk:ship / mk:resolving-merge-conflicts).

日本語の概要は準備中です。原文の説明を表示しています。

Fallback for general coding work that does not match any specific sextant sub-skill. Use for lightweight tasks: config changes, style fixes, utility functions, one-off scripts, or tasks too small to warrant a dedicated workflow. All dedicated sub-skills take priority over this one — check these first: sextant:fix-bug (broken behavior), sextant:debug (unknown bug location), sextant:add-feature (new functionality), sextant:modify-feature (changing existing behavior), sextant:review-code (evaluating code), sextant:write-tests (test coverage), sextant:refine-requirements (ambiguous scope), sextant:plan (multi-step sequencing), sextant:ship (release prep), sextant:migrate (cross-module upgrade), sextant:security (vulnerability audit). Only use this skill when none of the above match.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates initial and escalating dose for pubertal induction hormone therapy based on patient weight or body surface area. Triggers include patient eligible for sex hormone treatment, ready to start hormones.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends against initiating puberty blocking or gender-affirming hormone treatment in prepubertal children diagnosed with gender dysphoria or gender incongruence. Clinical triggers include a young child presenting with GD/gender incongruence and caregivers or clinicians considering hormone intervention.

日本語の概要は準備中です。原文の説明を表示しています。

Provides schedule for monitoring during sex hormone induction. Trigger: patient initiating gender-affirming hormone therapy (GAHT).

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether bone mineral density (BMD) measurement is indicated when patients have osteoporosis risk factors or have discontinued sex hormone therapy following gonadectomy. Clinical triggers include documented osteoporosis risk factors (e.g., low body weight, glucocorticoid use, prior fracture) or cessation of sex hormone therapy after surgical gonadectomy.

日本語の概要は準備中です。原文の説明を表示しています。

Selects spironolactone as first-line mineralocorticoid receptor antagonist for bilateral primary aldosteronism, with eplerenone as an alternative when spironolactone–related adverse effects are problematic. Trigger phrases include 'confirmed bilateral PA on AVS', 'idiopathic adrenal hyperplasia', 'bilateral adrenal hyperplasia', 'glucocorticoid-remediable aldosteronism', and 'initiating medical therapy for bilateral adrenal disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether to add a mineralocorticoid receptor antagonist (e.g., spironolactone or eplerenone) to glucocorticoid therapy in glucocorticoid-remediable aldosteronism when blood pressure fails to normalize with glucocorticoid alone. Triggered by persistent hypertension or inadequate BP control despite optimized glucocorticoid dosing in GRA patients.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests reducing the fludrocortisone dose in patients who develop new-onset hypertension while on fludrocortisone replacement for primary adrenal insufficiency. Consider dose reduction when hypertension arises alongside signs of mineralocorticoid excess such as edema, weight gain, or hypokalemia.

日本語の概要は準備中です。原文の説明を表示しています。

Determines unilateral vs bilateral aldosterone excess based on cortisol-corrected aldosterone ratios from adrenal venous sampling, with ratio >4:1 indicating unilateral excess, ratio 3:1 suggestive of bilateral hypersecretion, and interpretation dependent on cosyntropin stimulation protocol used during sampling. Use when analyzing AVS results to guide surgical vs medical treatment decisions; triggers include 'AVS lateralization ratio', 'cosyntropin-stimulated AVS', 'aldosterone-to-cortisol ratio >4:1', and 'ratio 3:1 suggestive of bilateral disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates the lowest effective glucocorticoid dose (dexamethasone or prednisone) to normalize blood pressure and serum potassium in glucocorticoid-remediable aldosteronism (GRA/FH-I) by titrating to biochemical and clinical targets. Indicated when initiating medical treatment for confirmed GRA, triggered by findings such as early-onset hypertension, family history of stroke before age 40, spontaneous hypokalemia, or suppressed plasma renin activity with elevated aldosterone.

日本語の概要は準備中です。原文の説明を表示しています。

Determines when to avoid aldosterone suppression testing in hypertensive patients with a positive PA screen who have normokalemia and suppressed aldosterone below assay‑specific cutoffs (<11 ng/dL immunoassay or <8 ng/dL LC‑MS/MS), indicating low likelihood of primary aldosteronism. Use when a clinician asks whether to skip confirmatory suppression testing based on low pretest probability.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends performing a dexamethasone suppression test to evaluate for autonomous cortisol secretion in patients with primary aldosteronism and adrenal adenoma. Triggered when a clinician considers whether to perform a dexamethasone suppression test in a patient with PA and adrenal adenoma.

日本語の概要は準備中です。原文の説明を表示しています。

Determines if primary aldosteronism is confirmed based on upright plasma aldosterone ≤6 ng/dL (170 nmol/L) on day 4 at 10 AM of fludrocortisone suppression test, provided plasma renin activity ≥1 ng/mL/h and plasma cortisol concentration lower than the 7 AM value to exclude ACTH confounding. Use when reviewing FST results to diagnose PA; triggers include "FST", "upright aldosterone ≤6 ng/dL", "PRA ≥1 ng/mL/h", and "cortisol drop".

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests using prednisolone as an alternative glucocorticoid when hydrocortisone is unavailable for emergency treatment of adrenal crisis. Dexamethasone is the least-preferred option and should only be administered if no other glucocorticoid is available.

日本語の概要は準備中です。原文の説明を表示しています。

This skill suggests initiating antihypertensive treatment while continuing fludrocortisone when blood pressure remains uncontrolled after fludrocortisone dose reduction. Trigger phrases include "BP remains uncontrolled," "persistent hypertension," or "elevated BP despite fludrocortisone adjustment."

日本語の概要は準備中です。原文の説明を表示しています。

Suite of tools for creating elaborate, multi-component claude.ai HTML artifacts using modern frontend web technologies (React, Tailwind CSS, shadcn/ui). Use for complex artifacts requiring state management, routing, or shadcn/ui components - not for simple single-file HTML/JSX artifacts.

日本語の概要は準備中です。原文の説明を表示しています。

Modern Angular UI patterns for loading states, error handling, and data display. Use when building UI components, handling async data, or managing component states.

日本語の概要は準備中です。原文の説明を表示しています。